Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Further US investment in AFT Pharmaceuticals

Further US investment in AFT Pharmaceuticals to advance international growth

Specialty Australasian pharmaceutical sales and development company, AFT Pharmaceuticals Ltd (AFT), has finalised a follow-on equity capital raise with CRG (formerly Capital Royalty L.P.), Atkinson family, AFT board members, and a group of specialist pharma investors from the United States.

The details of the financing are as follows: An additional US$7.5M in equity has been invested in AFT.

AFT’s founders, Atkinson Family interests, will retain almost 87% ownership of the company going forward. CRG will increase its existing shareholding to almost 9%.

Additional investment from the AFT board and specialist USA based pharmaceutical experts rounded out the equity raise which was oversubscribed based on significant demand from the USA.

“We are really pleased to see strong support from the United States,” said Dr Hartley Atkinson, Founder and CEO of AFT. “The US is widely recognised as the gold standard when it comes to pharmaceuticals. This is why the follow-on investment from CRG is especially pleasing as it’s a US-based investment expert in the health sciences field. To get this level of interest in an Australasian drug company is a big vote of confidence in AFT.”

“The additional investment from the Atkinson family and our board further reinforces internal support and belief in the future prospects for the business,” said Hartley Atkinson. “This new capital will be pivotal to maintaining momentum for our advanced R&D pipeline which is now starting to be commercialised in a number of countries around the world.”

While the business has focused on developing its R&D pipeline and putting in pace its licensing deals, it has also grown sales from NZ$66 to $76M in the last financial year.

This was driven by continuing growth in Australian product sales, together with international sales and royalties from its portfolio of novel drugs licensed to overseas biopharma companies. Sales from AFT’s newly established affiliates in Singapore and Malaysia also contributed to sales growth. A number of product launches in the Middle East and Europe will add to existing sales during this financial year.

AFT has an extensive, growing development portfolio of patented drug combination and Orphan Drug products and a unique drug device for intranasal delivery of therapeutic agents.

AFT will use the proceeds of this financing to continue its R&D activities and to initiate first pilot manufacturing of its novel drug delivery technology. AFT is also launching its patented combination analgesic, Maxigesic, in a number of territories around the world this financial year.

The company will also continue to out-license its prescription and over-the-counter products in distant regions/countries where it does not have an operating presence.

“To date, we have out-licensing and distribution agreements around the world and building upon these arrangements is an ongoing key activity with a number of additional agreements under both due diligence and negotiation,” said Hartley Atkinson.

ENDS

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Maritime Union: Deepening Supply Chain Crisis Requires Action

Maritime Union of New Zealand National Secretary Craig Harrison says the global COVID-19 pandemic exposed pre-existing weaknesses in our logistics sector, and created enormous problems... More>>



Air New Zealand: Employees Recognised With $1,000 Share Award

The efforts Air New Zealand employees made during one of the airline’s toughest years will be recognised via an award of $1,000 worth of company shares to all permanent employees... More>>

Consumer NZ: Bank Complaints On The Rise, Survey Shows

Nearly one in five Kiwis had a problem with their bank in the past year, Consumer NZ’s latest satisfaction survey finds. Consumer NZ chief executive Jon Duffy said the number of bank customers reporting problems had jumped to 18%, up from 11% in 2020... More>>

Mercury: Enters Into Binding Agreements To Acquire Trustpower’s Retail Business

Mercury NZ Limited (Mercury) has announced that it has entered into binding agreements with Trustpower Limited (Trustpower, NZX:TPW) to acquire Trustpower’s retail business for NZ$441 million... More>>

ALSO:


ASB: New Zealanders Missing Out On Hundreds Of Millions In KiwiSaver Government Contributions

New Zealanders have just over a week to ensure they’re eligible for the maximum annual government KiwiSaver contribution... More>>


Stats NZ: GDP Climbs 1.6 Percent In March 2021 Quarter Following December Dip

Gross domestic product (GDP) rose by 1.6 percent in the March 2021 quarter, following a 1.0 percent fall in the December 2020 quarter, Stats NZ said today. "After an easing of economic activity in the December quarter, we’ve seen broad-based growth in the first quarter of 2021... More>>